<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185793</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-201</org_study_id>
    <nct_id>NCT03185793</nct_id>
  </id_info>
  <brief_title>Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia</brief_title>
  <official_title>Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (Asymptomatic and Gout)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess efficacy and safety of SHR4640 in subjects with
      hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a serum uric level≤360μmol/l.</measure>
    <time_frame>Week 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actual change from baseline in serum uric level.</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in serum uric level .</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gout flares requiring treatment.</measure>
    <time_frame>Up to week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gout flares requiring treatment.</measure>
    <time_frame>Up to week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a serum uric level≤360μmol/l</measure>
    <time_frame>At week1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a serum uric level consistent ≤360μmol/l</measure>
    <time_frame>At week 3, 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual change from baseline in serum uric level</measure>
    <time_frame>At week 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in serum uric level</measure>
    <time_frame>At week 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5mg SHR4640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg SHR4640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg SHR4640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg benzbromarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzbromarone for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 5 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks</description>
    <arm_group_label>2.5mg SHR4640</arm_group_label>
    <arm_group_label>5mg SHR4640</arm_group_label>
    <arm_group_label>10mg SHR4640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benzbromarone</intervention_name>
    <description>25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks</description>
    <arm_group_label>50mg benzbromarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-70 years, male or female;

          2. Subject meets one of the following conditions:

        1) Subject with a history of gout has a serum uric acid ≥480μmol/l at screening; 2) Subject
        with a history of hyperuricemia has a serum uric acid ≥540μmol/l at screening, and
        requiring long-term uric acid-lowering therapy per the investigator's judgment; 3) Subject
        with a history of hyperuricemia has a serum uric acid≥480μmol/l at screening, on stable
        treatment for hypertensive, hyperlipidemia or diabetes for at least 3 month, and requiring
        long-term uric acid-lowering therapy per the investigator's judgment; 3. 18kg/m2≤ BMI
        ≤32kg/m2.

        Exclusion Criteria:

          1. Subject who is pregnant or breastfeeding;

          2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin＞1.5 upper
             normal limit;

          3. Estimated glomerular filtration rate (MDRD formula) ˂60ml/min;

          4. HbA1c˃8%;

          5. Subject with known hypersensitivity or allergy to SHR4640 or any component of SHR4640;

          6. Subject with a history of malignancy;

          7. Subject with a history of urolithiasis, or positive findings on ultrasound examination
             at screen

          8. Subject within the last 3months has: myocardial infarction, angina, percutaneous
             transluminal coronary angioplasty, coronary artery bypass grafting, cerebral
             infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia
             attack;

          9. Subject has acute gout flares within 2 weeks before randomization;

         10. Subject who is taking any other urate-lowering medication (allopurinol, febuxostat,
             probenecid and benzbromarone) that is indicated within 2 weeks before randomization
             and can not stop during the study;

         11. Subject who is taking more than 100mg once daily or unstable dosage aspirin within 2
             weeks before randomization and can not stop during the study;

         12. Subject who is taking any diuretic within 2 weeks before randomization and can not
             stop during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunde Bao</last_name>
    <role>Principal Investigator</role>
    <affiliation>shanghai Jiaotong University, School of Medicine, Renji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan-Ping Liu, Ph.D.</last_name>
    <phone>86(21)68868571</phone>
    <email>liuyanping@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Lan, Ph.D.</last_name>
    <phone>86(21)68868571</phone>
    <email>lanyang@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Hengrui Medicine Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunde Bao, Master</last_name>
      <phone>8613601689747</phone>
      <email>baochunde_1678@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR4640, Phase II, monotherapy, dose-finding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzbromarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

